Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.

Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.

Key Inclusion Criteria:

• Diagnosis of RA (functional class I - III)
• Stable dose of MTX
• Inadequate response to at least one conventional DMARD therapy

Key Exclusion Criteria:

• Serious local infection or systemic infection
• History (Hx) of recurrent infections requiring oral or parenteral anti-infective treatment
• Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period
• Clinical significant lab tests at screening
• Positive for Hep C or Hep B at screening

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.